• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Health technology assessment framework: adaptation for digital health technology assessment]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Ambulatory blood pressure monitoring (ABPM) in the identification of circadian patterns in patients with arterial hypertension: evaluation of safety, effectiveness, and efficiency]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Stereotactic radiosurgery for the treatment of epilepsy, essential tremor, Parkinson's disease, glossopharyngeal and trigeminal neuralgia: synthesis of its efficacy, effectiveness, safety, and efficiency]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Primary bariatric endoscopic techniques in adults with or without type 2 diabetes mellitus. Efficacy, effectiveness, and safety]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Key items for developing and implementing a high complexity/cost surgical implants registry for its postmarketing surveillance]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional therapy in heart failure patients with malnutrition]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Implantable automatic defibrillator for primary prevention of sudden cardiac death in Spain: efficacy, safety, and efficiency]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Automated storage and dispensing medication systems in hospital pharmacy services. Safety, effectiveness and efficiency]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of mHealth-based technology for mobile applications]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional treatment of multi-morbid patients in a state of malnutrition]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional treatment of patients with chronic obstructive pulmonary disease in a state of malnutrition]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of active spiritual healing]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, effectiveness and efficiency of glucometers, gasometers and coagulometers]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Platform to analyse RNA, DNA or proteins as biomarkers in the diagnosis, prognosis and assessment of treatments]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the effectiveness of hip and knee implant models used by the Spanish National Health System]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Next-generation sequencing (NGS) for molecular diagnosis and the selection of therapeutic targets in oncology]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Patients with hip fracture from low-impact trauma: clinical management of anti-osteoporotic pharmacological treatment to prevent new fractures]
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of the pilates method in selected clinical conditions]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Review of the evidence on the impact of school closures through the evolution of the COVID-19 pandemic]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Fall-safe assist. Portable device for falls prevention]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficiency of 3D reconstruction in maxillofacial surgery]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Halcyon intensity-modulated beam conformal image-guided volumetric radiotherapy system for oncology treatment]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evidence on the personalization of population-based breast cancer screening]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Cerenkov lluminescence imaging system for intraoperative assessment of surgical margins in breast, prostate, and gastrointestinal cancer]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Economic, organization and safety impact of drug robotic dispensing in Spanish hospitals]
2019     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Powder bed fusion manufacturing of titanium for customized bone replacements in craneomaxillofacial reconstruction]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Computerized clinical decision support systems for decision support in patients with breast, lung, colorectal or prostate cancer]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Assessment of the volume-result relationship in specialized care of pediatric cancer]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Femoral neck fracture: evaluation of the hospital care process]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of bariatric surgery in individuals with morbid obesity]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy, safety, and usefulness of genistein in patients with Sanfilippo syndrome]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Analysis of diagnostic performance of transbronchial lung biopsy using cryoprobe (cryobiopsy) in the study of diffuse lung diseases]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment. Update]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Shoulder arthroscopy: appropriate use]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Effectiveness and cost-effectiveness of bilateral cochlear implants in children and adults]
2022     Agency for Care Effectiveness (ACE) Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022     Agency for Care Effectiveness (ACE) Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022     Agency for Care Effectiveness (ACE) The PrecivityAD test for the prognosis of Alzheimer's disease
2022     Agency for Care Effectiveness (ACE) Artificial intelligence and its clinical applications
2022     Agency for Care Effectiveness (ACE) 3D printing and its clinical applications
2022     Agency for Care Effectiveness (ACE) Overview of clinical applications of telemedicine
2022     Agency for Care Effectiveness (ACE) Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2018     Agency for Care Effectiveness (ACE) 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET-CT) for oncological indications
2019     Agency for Care Effectiveness (ACE) Video capsule endoscopy for diagnosing obscure gastrointestinal bleeding
2022     Agency for Care Effectiveness (ACE) Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2019     Agency for Care Effectiveness (ACE) Ambulatory sleep study for diagnosing obstructive sleep apnoea
2022     Agency for Care Effectiveness (ACE) Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2020     Agency for Care Effectiveness (ACE) Acupuncture for adults with low back pain and neck pain
2021     Agency for Care Effectiveness (ACE) MRI-US fusion targeted biopsy for diagnosis of prostate cancer
2021     Agency for Care Effectiveness (ACE) Transcatheter mitral valve leaflet repair for patients with mitral regurgitation
2021     Agency for Care Effectiveness (ACE) Transcatheter aortic valve implantation (TAVI) for patients with symptomatic severe aortic stenosis
2021     Agency for Care Effectiveness (ACE) Photodynamic therapy for treating non-melanoma skin tumours
2021     Agency for Care Effectiveness (ACE) Cochlear implants for treating adults with single-sided deafness (SSD)
2021     Agency for Care Effectiveness (ACE) Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections
2021     Agency for Care Effectiveness (ACE) Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2021     Agency for Care Effectiveness (ACE) Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2017     Agency for Care Effectiveness (ACE) Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2017     Agency for Care Effectiveness (ACE) Gliclazide for the treatment of type 2 diabetes mellitus
2017     Agency for Care Effectiveness (ACE) Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis
2020     Agency for Care Effectiveness (ACE) Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2017     Agency for Care Effectiveness (ACE) Somatropin for the treatment of growth failure in children
2017     Agency for Care Effectiveness (ACE) Gemcitabine for the treatment of cancer
2017     Agency for Care Effectiveness (ACE) Sumatriptan for the treatment of acute migraine attacks
2017     Agency for Care Effectiveness (ACE) Temozolomide for the treatment of malignant glioma
2017     Agency for Care Effectiveness (ACE) Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Guardant360 CDx for patients with locally advanced or metastatic non-small cell lung cancer
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults
2022     Agency for Care Effectiveness (ACE) The Signatera test for patients previously diagnosed with cancer
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2018     Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2018     Agency for Care Effectiveness (ACE) LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2020     Agency for Care Effectiveness (ACE) Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
2022     Agency for Care Effectiveness (ACE) Nivolumab for treating gastroesophageal cancers
2018     Agency for Care Effectiveness (ACE) Solifenacin for treating overactive bladder
2022     Agency for Care Effectiveness (ACE) Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2022     Agency for Care Effectiveness (ACE) SGLT2 inhibitors for treating heart failure with reduced ejection fraction and chronic kidney disease
2018     Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2022     Agency for Care Effectiveness (ACE) Cabozantinib in combination with nivolumab for previously untreated advanced renal cell cancer
2018     Agency for Care Effectiveness (ACE) Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C